Jeff L. Vacirca - Jun 17, 2025 Form 3 Insider Report for Caris Life Sciences, Inc. (CAI)

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Stock symbol
CAI
Transactions as of
Jun 17, 2025
Transactions value $
$0
Form type
3
Date filed
6/17/2025, 09:36 PM
Previous filing
Jun 12, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vacirca Jeff L Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 2025-06-17 0001724161

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAI Common Stock 16.1K Jun 17, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAI Stock Option Jun 17, 2025 Common Stock 25K $17.16 Direct F2
holding CAI Stock Option Jun 17, 2025 Common Stock 75K $19.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
F2 The stock option vests in five substantially equal annual installments beginning on February 23, 2023.
F3 The stock option vests in five substantially equal annual installments beginning on November 7, 2025.

Remarks:

Exhibit 24 - Power of Attorney.